Eddie Hickman
Stock Analyst at Guggenheim
(4.43)
# 317
Out of 5,141 analysts
20
Total ratings
68.42%
Success rate
20.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PMN ProMIS Neurosciences | Maintains: Buy | $125 → $35 | $16.09 | +117.53% | 4 | Feb 6, 2026 | |
| ATAI AtaiBeckley | Initiates: Buy | $11 | $3.88 | +183.51% | 1 | Jan 20, 2026 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $84 → $87 | $66.61 | +30.61% | 9 | Nov 5, 2025 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | n/a | $0.41 | - | 4 | Aug 29, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $8.80 | +150.00% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $15.60 | +105.19% | 1 | Mar 13, 2025 |
ProMIS Neurosciences
Feb 6, 2026
Maintains: Buy
Price Target: $125 → $35
Current: $16.09
Upside: +117.53%
AtaiBeckley
Jan 20, 2026
Initiates: Buy
Price Target: $11
Current: $3.88
Upside: +183.51%
Tarsus Pharmaceuticals
Nov 5, 2025
Maintains: Buy
Price Target: $84 → $87
Current: $66.61
Upside: +30.61%
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.41
Upside: -
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $8.80
Upside: +150.00%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $15.60
Upside: +105.19%